#Canada #Toronto #Biologics #AmacaThera #AmacaGel

AmacaThera Ventures Into Innovative Drug Delivery

In an impressive stride towards advancing drug delivery technology, AmacaThera, a promising clinical-stage biotechnology firm, has announced its collaboration with a renowned global pharmaceutical company. Their joint effort aims to develop an innovative single-injection, long-acting biologic utilizing AmacaThera's proprietary hydrogel delivery platform, known as AmacaGel™. This partnership reflects a significant step in harnessing cutting-edge technologies to improve therapeutic solutions for patients.

Collaboration Details

Through this new pipeline program, both parties will leverage their unique strengths to enhance the development of this biologic, co-funding the venture to ensure that both companies can contribute resources effectively. "We are thrilled to collaborate on this promising venture," stated Molly Shoichet, Chief Scientific Officer at AmacaThera. The synergy between AmacaThera’s technological expertise and the pharmaceutical company's therapeutic insights promises considerable advancements in drug delivery.

The partnership comes on the heels of the successful Phase 1 clinical trial, evaluating AmacaGel™ in conjunction with an anesthetic. This trial produced valuable human data, demonstrating the reliable integration of the hydrogel platform with various therapeutic agents, from small molecules to complex biologics and even stem cells.

Innovations in Drug Delivery

Mike Cooke, CEO of AmacaThera, emphasized the potential of this collaboration, remarking, "This cooperation allows us to build on our manufacturing experience and the human data collected from our hydrogel platform, facilitating the rapid development of effective solutions to injectable delivery challenges." One of the distinctive features of AmacaGel™ is its compatibility with diverse drug modalities, coupled with a streamlined, cost-effective manufacturing process. By creating an environment where hydrogel formulations can thrive, AmacaThera aims to address substantial obstacles in drug delivery.

Hydrogels have a long history in research; however, AmacaThera’s approach sets its platform apart. It relies on a combination of two well-established polymers that allow for rapid delivery through a conventional syringe, forming a depot once it reaches body temperature. This is crucial for patients requiring long-acting therapeutics, particularly in areas like pain management and oncology, where consistent and extended relief is vital.

Future Perspectives

The alliance was facilitated by CQDM's Connect-Pharma program, designed to foster collaborations between Canadian entities and pharmaceuticals. CQDM is committed to innovating through multi-stakeholder collaborations aimed at accelerating the transition of technologies from laboratory phases to patient applications. CQDM Board Member Raphael Hofstein expressed the organization's excitement regarding AmacaThera's progress from bench to bedside, stating that this collaboration further exemplifies the industry's confidence in their platform.

Mark Steedman, a Senior Business Development Director at CQDM, added, "We are excited to have brought this collaboration together and believe that the minimized risks associated with AmacaThera’s technology could lead to expedited project advancement and valuable data generation within a short timeframe."

About AmacaThera

Founded with the mission of revolutionizing drug delivery, AmacaThera has positioned itself as a leader in the biopharmaceutical space. With an unwavering focus on sustained-release hydrogel formulations, the company addresses significant challenges faced in therapeutic drug delivery today. Their leading product, AMT-143, serves as a slow-release non-opioid anesthetic, showcasing the innovative potential of AmacaGel™ technology in promoting effective post-operative pain management.

To learn more about AmacaThera and its ambitious plans, visit www.amacathera.com.

Now, as it embarks on this collaborative journey, AmacaThera continues to drive innovation across vital therapeutic areas, promising a future where enhanced patient outcomes are no longer a distant goal but a tangible reality.